GSK pays $1.2B upfront for Boston's lead liver disease drug

10 hours ago 1

This communicative appeared connected fiercebiotech.com, 2025-05-14 21:44:20.683000.

Read Entire Article
  1. Homepage
  2. Local
  3. GSK pays $1.2B upfront for Boston's lead liver disease drug

Related

Russia-Ukraine Talks: Trump Keeps Door Open to Turkey Trip

Russia-Ukraine Talks: Trump Keeps Door Open to Turkey Trip

12 minutes ago 0
Amazon Is Quietly Building An AI Empire

Amazon Is Quietly Building An AI Empire

12 minutes ago 0
CPSC Warns Consumers to Immediately Stop Using Certain Chinese-Made Faucets Sold on Amazon.com Due to Dangerous Lead Exposure for Infants, Young Children and Pregnant Women

CPSC Warns Consumers to Immediately Stop Using Certain Chine...

12 minutes ago 0
Tencent bets on 1.4 billion user WeChat empire to get ahead in China's AI race

Tencent bets on 1.4 billion user WeChat empire to get ahead ...

12 minutes ago 0
Dogecoin, Cardano and Solana Slump as Crypto Majors See Profit-Taking After Week-Long Rally

Dogecoin, Cardano and Solana Slump as Crypto Majors See Prof...

12 minutes ago 0
European shares drop as energy sector drags; Fed's Powell, key US data in focus

European shares drop as energy sector drags; Fed's Powell, k...

12 minutes ago 0

Trending

Popular

Fake PayPal email let hackers access computer and bank account

Fake PayPal email let hackers access computer and bank accou...

17 hours ago 133
Governor Healey announces Executive Branch hiring freeze amid economic uncertainty

Governor Healey announces Executive Branch hiring freeze ami...

15 hours ago 48
The Environmental Protection Agency delays limits on PFAS in drinking water

The Environmental Protection Agency delays limits on PFAS in...

10 hours ago 38
Ken Fisher's Strategic Moves: Amazon.com Inc. Sees a -1.1% Portfolio Impact

Ken Fisher's Strategic Moves: Amazon.com Inc. Sees a -1.1% P...

14 hours ago 34
Why Exelixis, Inc. (EXEL) Skyrocketed On Wednesday

Why Exelixis, Inc. (EXEL) Skyrocketed On Wednesday

7 hours ago 32
English (US) English (US) ·
About Us · Contact Us · Terms & Conditions ·

© nkomode 2025. All rights are reserved